Short at­tack tar­gets one of the fa­vorites now shar­ing the lead in the pop­u­lar KRAS drug de­vel­op­ment race

Sahm Ad­ran­gi’s short-at­tack team at Ker­ris­dale is out to slam one of the most pop­u­lar biotech plays in the book this morn­ing.

The tar­get is Mi­rati $MRTX, which has swift­ly built a multi­bil­lion-dol­lar val­u­a­tion around the idea that it can ri­val Am­gen in an his­toric race to the mar­ket with the first KRAS G12C drug in non-small cell lung can­cer.

Ac­tu­al­ly, Ad­ran­gi and his crew don’t much care for ei­ther Mi­rati’s MRTX-849 or Am­gen’s AMG510. But Mi­rati is close to a pure-play KRAS propo­si­tion now, mak­ing the stock vul­ner­a­ble to the kind of bear­ish maul­ing that Ker­ris­dale likes to in­flict on its sub­jects.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Senior Associate

Alexandria Real Estate Equities

Durham, NC, USA